Pfizer reveals reorganization, executive departure as it gets ready to close $43B Seagen buyout

To complete its acquisition of Seagen, what did Pfizer need to do to satisfy antitrust concerns of the Federal Trade Commission?

By agreeing to donate royalties on its U.S. sales of bladder cancer drug Bavencio to the American Association for Cancer Research (AACR), Pfizer has received the go-ahead to finalize its $43 billion buyout of the Seattle biotech, the company said on Tuesday.